CLUE
17.11.2021 01:03:12 CET | Business Wire | Press release
Clue, a SaaS platform for managing investigations, today announced growth investment of £5 million from Frog Capital, a leading investor in European scale-up software. Demand for Clue has more than doubled over the last two years, driven by co-owners Clare Elford, CEO, and Thomas Drohan, CCO. From its roots in policing, the platform is now used across government, private and non-profit sectors to investigate cyber-crime, fraud, child protection, corruption, environmental crime, cheating in sports and much more. Clare and Thomas are joined on the board of directors by Nick Harber, CFO; Mike Reid, Senior Partner at Frog Capital; and Adam Hale, Chair of the ScaleUp Institute, as Chairman.
Clare Elford, CEO, said: “The world of intelligence and investigations is no longer constrained to policing, there is much wider application. Organisations are under growing scrutiny, finding themselves more susceptible to threats and with a much greater duty of care towards the vulnerable.
“Clue has productised decades of investigation expertise into a platform that empowers intelligence officers and investigation experts to achieve successful outcomes. So many of those dedicated to preventing harm and seeking justice have to deal with an overwhelming volume and complexity of data. Still reliant on legacy systems, or even spreadsheets, this is a sector primed for digital transformation.”
Thomas Drohan, CCO, said “With this investment, we will strengthen the capabilities of the platform with further AI and ML capability, automation, data insights and business intelligence, while continuing to support and build our user community. Frog have a formidable track record, with an impressive team who we are looking forward to working with to deploy the Scale-up Methodology and drive business growth and a solution to better serve the market.”
Mike Reid, at Frog Capital who joins Clue’s board said: “Across the industries that Clue serves there's a deep-rooted frustration at the lack of good enough tech to allow people to do their investigative work as efficiently and thoroughly as they need. For too long there's been a staggering underinvestment in how investigations are done, resulting in missed opportunities and slow outcomes for hardworking investigative teams and the people they serve.
“Clue's technology is genuinely delivering very significant clients a step change in how they manage and resolve incredibly complex and sensitive investigation cases. With Frog’s investment and experienced team of operators, Clue can accelerate their incredibly positive organisational and, critically, social impact in the key fields of policing, child welfare, financial crime amongst many others.”
Clue’s new Chairman, Adam Hale, said: “'I first met Clare and Thomas just before the pandemic and was really impressed with what they had built and the magnitude of customer problem that Clue solves. Since then, working with the ScaleUp Group, they have raised value-added SaaS growth investment from Frog Capital. I have known Frog for many years and am delighted to become part of their portfolio. I'm also really excited to work with Nick Harber again. I studied Computer Science in Bristol in the 80s and love coming back to a city set to support high growth organisations such as Clue.
“Now is the 'end of the beginning' for Clue and the start of the path to market leadership. From speaking to customers, I can hear how invaluable Clue is to them. There is so much opportunity and I'm thrilled to be part of it.”
About Clue
Clue is a cloud-based investigation case management and intelligence platform that enables organisations to prevent harm and secure justice by building intelligence and quickly progressing investigations in the face of evolving threats, increasing volumes of data, and the need for multi-agency collaboration.
About Frog Capital
Frog Capital is a specialist software Scale-Up Investor in high-growth European software companies and software-enabled businesses at the Scale-Up stage. Frog has a team of in-house operating partners who actively support their portfolio at executive level across the wide range of business challenges they face. Frog has combined over 20 years of experience to create its unique Scale-Up Methodology, which provides a framework defining the major elements of success through the Scale-Up phase.
View source version on businesswire.com: https://www.businesswire.com/news/home/20211116005095/en/
Link:
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Askey and Canoga Perkins Announce Strategic Collaboration at MWC Barcelona to Deliver Rapid-Deploy 5G Critical Communications Solutions27.3.2026 12:00:00 CET | Press release
Askeyand Canoga Perkinsannounced at Mobile World Congress Barcelona a Global Partnership to Deliver SyncMetra® Network Connectivity Solution, combining Canoga Perkins’ software-defined, IT-operated private 5G network transport along with Askey’s carrier-grade 5G radio access technology. At MWC Barcelona 2026, Askey Computer Corporation and Canoga Perkins announced a strategic partnership to deploy Canoga Perkins' SyncMetra® Platform across enterprise and service provider markets with Askey. This partnership pairs Askey’s carrier-grade radio access capabilities with Canoga Perkins’ industry-leading time-sensitive networking (TSN) and synchronization technology, enabling customers to simplify deployment of ultra-low-latency, highly reliable network services for 5G, edge compute, industrial automation, and mission-critical enterprise applications. The partnership enables joint go-to-market efforts, integrated product offerings, and expanded access to SyncMetra through Askey’s sales channe
SBC Medical Announces Fourth Quarter and Full Year 2025 Financial Results27.3.2026 11:40:00 CET | Press release
Q4 EPS more than doubles to $0.14 as profitability improves significantly year over year SBC Medical Group Holdings Incorporated (Nasdaq: SBC) (“SBC Medical” or the “Company”), a Management Services Organization operating a wide range of franchise businesses across diverse medical fields, today announced its financial results for the fourth quarter of fiscal year 2025 (three months ended December 31, 2025) and for the full fiscal year 2025 (twelve months ended December 31, 2025). Fourth Quarter 2025 Highlights Total revenues were $40 million, representing an 11% year-over-year decrease. Net Income attributable to SBC Medical Group was $14 million, representing a 117% year-over-year increase. Earnings per share, which is defined as net income attributable to the Company divided by the weighted average number of outstanding shares, was $0.14 for the three months ended December 31, 2025, representing 133% year-over-year increase. EBITDA1, which is calculated by adding depreciation and amo
NIQ Redefines Packaging Intelligence with Monthly, Harmonized Global Performance Visibility27.3.2026 11:00:00 CET | Press release
NIQ’s new solution brings unprecedented clarity into package types, materials, and true consumption across markets, closing critical industry gaps NielsenIQ (NYSE: NIQ), a global leader in consumer intelligence, today announced the launch of its Packaging Strategic Planner Global (SPG) Solution, the first harmonized global platform to deliver monthly visibility into packaging performance across materials, formats, and pack configurations. As packaging innovation accelerates, many organizations continue to rely on fragmented or annual data to inform packaging decisions. The Packaging SPG Solution closes this gap by providing real-time data delivered monthly across regions, enabling brands and packaging partners to uncover trends, grow revenue, and strengthen relationships with CPG and retail partners. Key Highlights: New monthly global packaging tracking capability Coverage across 200+ categories Visibility into 30+ package types and 20 package materials 10+ markets at launch, expanding
European DataWarehouse Claims Its First “Fintech Provider of the Year” Award and a Sixth “Data Provider of the Year” Title at GlobalCapital’s 2026 European Securitisation Awards27.3.2026 08:47:00 CET | Press release
European DataWarehouse (EDW) is pleased to announce that it has been named both “Data Provider of the Year” and “Fintech Provider of the Year” at the 2026 GlobalCapital European Securitization Awards in London. The award ceremony recognises outstanding achievements in European structured finance, with winners selected by popular vote from across the industry. As defined by GlobalCapital, the programme celebrates “the very best in the market, as chosen by the market.” This latest recognition marks the sixth time that EDW has received the prestigious Data Provider of the Year award, having previously been honoured in 2019, 2022, 2023, 2024 and 2025, reaffirming its long-standing commitment to transparency, data quality and innovation in European securitisation. Prof. José Manuel González-Páramo, Chairman of EDW, later commented: “ Winning this award for the sixth time highlights the continued trust the European securitisation market places in EDW. Transparency, data quality and reliabili
Biocytogen Announces FDA IND Clearance for Partner NEOK Bio’s NEOK002 Targeting Solid Tumors27.3.2026 01:00:00 CET | Press release
Biocytogen Pharmaceuticals (Beijing) Co., Ltd. (Biocytogen, SSE: 688796; HKEX: 02315), a global biotechnology company that drives the research and development of novel antibody-based drugs with innovative technologies, today announced that its partner NEOK Bio, Inc. recently received clearance from the U.S. Food and Drug Administration (FDA) of an investigational new drug (IND) application for NEOK002, an EGFR/MUC1-targeting ADC program for solid tumors. NEOK Bio plans to initiate a Phase 1 clinical study in the second quarter of 2026 and expects to report initial data in 2027. This IND clearance marks an important milestone for NEOK002, an EGFR/MUC1-targeting ADC candidate developed by NEOK Bio and built on a bispecific antibody originally developed by Biocytogen and licensed in 2024. According to NEOK Bio, NEOK002 is being advanced for solid tumors and may offer differentiated efficacy and safety compared with monospecific ADC approaches directed at either target alone. Dr. Yuelei Sh
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom
